Anti-Mullerian Hormone (AMH) is an essential biomarker in reproductive medicine, serving as a proxy for ovarian reserve. AMH is produced by granulosa cells in small growing follicles and reflects the remaining egg supply. When a blood test shows that AMH is low, it is usually either that the number of eggs is decreasing at a rate not typical for a person's age or that the number of eggs has reached a natural low.
This article explains the biology of AMH, the exact ranges of numbers that constitute low versus normal, and the different aspects, from genetics to lifestyle, that determine these outcomes. This article will also demonstrate the distinction between egg quantity and egg quality, the influence of low AMH on the success of natural conception and assisted reproductive technologies such as IVF, and the diagnostic procedures that help provide a diagnosis of diminished ovarian reserve.
Anti-Mullerian hormone is a protein hormone synthesised by the granulosa cells in the small, pre-antral and early antral follicles in the ovaries. These follicles are the "resting" eggs that have not yet been selected for ovulation. Because AMH is produced by these developing follicles, the amount of the hormone present in the blood generally correlates the total number of eggs left in the ovaries.
In reproductive biology, AMH helps regulate follicle development. It helps control the number of follicles recruited, so the ovaries progressively decline in ovarian reserve. As opposed to other fertility hormones that vary irregularly during the month, AMH levels do not change a lot during the menstrual cycle. It is a useful diagnostic tool because it can assess ovarian reserve, or the ovarian reserve, at one time due to its stability.
Clinicians assess AMH by using a basic blood test. In contrast to Follicle-Stimulating Hormone (FSH), which physicians must test on the second or third day of a menstrual cycle, an AMH test can be done on any day. This is convenient and, therefore, is one of the most ordered tests in a fertility workup.
The lab measures the concentration of AMH in serum, typically in nanograms per millilitre (ng/mL). This test is often performed in combination with a transvaginal ultrasound by doctors to conduct an Antral Follicle Count (AFC). Although the AMH test provides a biochemical measure of ovarian reserve, AFC provides a visual count. A combination of the two metrics provides a more accurate assessment of a patient's current reproductive potential.
Although laboratory normal ranges may vary slightly, the medical community generally provides standardised benchmarks for interpreting AMH results. The levels assist in classifying the ovarian reserve into certain levels:
The result of a low reading means that the ovaries have a lower number of resting follicles than usual. However, clinicians interpret these values based on age. It may be reasonable to expect a level of 0.8 ng/mL in someone in their mid-40s, but it is worryingly low for someone in their late 20s.
There are several causes of a decrease in AMH. Some of them are normal aspects of ageing, whereas others are pathological or environmental.
This is one of the most misunderstood aspects of fertility testing. Quantity, not quality, is measured in AMH. Low AMH means there are fewer eggs, but it does not indicate anything about the health of the chromosomes or the viability of the eggs. In this case, a 28-year-old patient with low AMH (0.6 ng/mL) is unlikely to have low-quality eggs, as her age indicates that the majority of her remaining eggs will have normal chromosome composition. On the other hand, a 43-year-old with a normal AMH level (1.1 ng/mL) might have numerous eggs, but most are likely to be chromosomally abnormal due to age-related wear and tear.
Low AMH makes it more difficult to find a good egg during a fertility cycle, but it does not mean a viable egg may still be present.
Yes, with low AMH, natural conception is still possible. Since a natural pregnancy will only need the release of one fertilised egg each month, an individual with a low reserve can still release a high-quality egg and become a mother.
Low AMH does not predict the chance of pregnancy in a given month, but it predicts how much time an individual has before they may experience depletion of ovarian reserve. It also anticipates the poor response they would give to high doses of hormones administered during IVF. A low AMH may have a reduced period of fertility, but they are not always infertile in the short term.
Age is the primary factor used to interpret AMH levels. The normal range of AMH declines with age.
When AMH is very low, compared to the average of the age group, a diagnosis of Diminished Ovarian Reserve (DOR) is made. A 25-year-old with a reading of 1.0 ng/mL is a significant alarm; a 42-year-old with 1.0 ng/mL is a good indicator.
Beyond the natural ageing process, specific clinical conditions can compromise the ovaries.
Lifestyle changes cannot "grow" new eggs. However, they can potentially stabilise the environment in which the remaining follicles live.
When AMH is low, fertility clinics often adjust their protocols to maximise the chances of retrieving the few eggs that remain.
There is no proven medical way to increase the total number of eggs in the ovaries once they are gone. Nonetheless, some supplements are commonly used to improve the performance of the remaining eggs and the precision of the AMH test.
Coenzyme Q10 (CoQ10) and DHEA are commonly used in patients with low AMH. DHEA, a precursor hormone, can make follicles more responsive to stimulation, and in some cases, patients experience a slight increase in AMH levels after several months of supplementation. It does not imply that new eggs were formed, but it indicates that those follicles that were previously dormant or silent are now forming enough hormones to be observed.
A low AMH result can be concerning, but it does not eliminate the possibility of pregnancy. It recognises a depletion of the number of the egg supply- the ovarian reserve- but it is not a conclusive determination of the quality of those eggs or the capacity to carry a healthy pregnancy.
In the younger people, low AMH is a wake-up call to act promptly, perhaps by considering egg freezing or hastened fertility procedures. For individuals later in their reproductive years, it would help determine realistically whether reproductive procedures, such as IVF, would be successful. By combining AMH testing with other diagnostics, such as AFC and FSH, medical experts can develop highly individualised plans. Finally, low AMH is also an empowering tool; it provides data that enables informed, timely decisions about family building and hormonal health, helping patients make the most effective choices moving forward.